Asthma is fundamentally a disease of inflammation1,2
Uncontrolled inflammation causes the symptoms of asthma 3
Bronchoconstriction can be the result of uncontrolled inflammation3
Guidelines recommend anti-inflammatory therapy early in the disease1
Cysteinyl leukotrienes are powerful mediators of inflammation not blocked by steroids4,5
Cysteinyl leukotrienes are important in early asthma and throughout the disease 6-10
Cysteinyl leukotrienes are highly specific to a single receptor but catalyze a massive inflammatory cascade 5
Cysteinyl leukotrienes in the airways are not blocked by steroids 5
CONTROL INFLAMMATION BY TARGETING THE DUAL PATHWAYS OF INFLAMMATION
Cysteinyl leukotrienes and steroid-sensitive mediators form two critical pathways of inflammation4,5,9,11-14
Leukotriene-mediated pathways of inflammation in the airway are not blocked by steroids15
Treating dual pathways of inflammation in a clinical study provided better control of inflammation as shown by the significant reduction of clinical markers of inflammation (eosinophils)16
SINGULAIR DELIVERS EFFECTIVE ASTHMA CONTROL FAST16-18
SINGULAIR improved asthma control from day 1 as assessed by reduced B-agonist use in a clinical trial17
SINGULAIR provides excellent tolerability comparable to placebo
SINGULAIR is easy to take – 1 tablet or 1 sachet, once a day
SINGULAIR provides flexible dosing options with three once-daily formulations – tablets, chewable tablets, or oral granules
For children, SINGULAIR is now approved for use in patients as young as 6 months old in some countries*
Parents and children with asthma** alike preferred SINGULAIR over inhaled therapy (cromolyn) in an open-label trial (n= 266)19
SINGULAIR is not a steroid, and not associated with potential risks of steroids
*The experience in use in pediatric patients 6 to 12 months of age is limited
**Aged 6 to 11
